Cardiovascular risk reduction more prominent with EPA monotherapy versus EPA + DHA therapy<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, July 12, 2021 (HealthDay News) — Omega-3 fatty acids (FAs) are associated with lower cardiovascular mortality and improved cardiovascular outcomes, according to a review published online July 8 in eClinicalMedicine<\/em>.<\/p>\n Safi U. Khan, M.B.B.S., from West Virginia University in Morgantown, and colleagues conducted a systematic literature review to determine the effectiveness of omega-3 FAs on fatal and nonfatal cardiovascular outcomes. The meta-analysis included 38 randomized controlled trials (149,051 participants) of omega-3 FAs, stratified by eicosapentaenoic acid (EPA) monotherapy and EPA + docosahexaenoic acid (DHA) therapy.<\/p>\n The researchers found that omega-3 FA intake was associated with reductions in cardiovascular mortality (rate ratio [RR], 0.93), nonfatal myocardial infarction (MI; RR, 0.87), coronary heart disease (CHD) events (RR, 0.91), major adverse cardiovascular events (MACE; RR, 0.95), and revascularization (RR, 0.91). EPA monotherapy was associated with higher risk reductions than EPA + DHA for cardiovascular mortality, nonfatal MI, CHD events, MACE, and revascularization. However, omega-3 FA increased incident atrial fibrillation (RR, 1.26), while EPA monotherapy was associated with a higher risk for total bleeding (RR, 1.49) and atrial fibrillation (RR, 1.35) compared with control.<\/p>\n “This study provides evidence regarding the therapeutic efficacy of omega-3 FAs and may explain the conflicting results between EPA monotherapy trials and those with EPA + DHA,” the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.<\/p>\n